Stockscreener 앱 받기
10.98
3.35%
-0.38
Trevi Therapeutics Inc 주식(TRVI)의 최신 뉴스
TRVI Stock Falls -15% With A 7-day Losing Spree On Technical Breakdown - Trefis
Will Trevi Therapeutics Inc. stock rally after Fed decisions2026 world cup usa national team qualification young talents transition play match prediction tactical review - Улправда
Published on: 2026-01-03 15:10:39 - moha.gov.vn
Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 6.3%Here's Why - MarketBeat
Quarterly Recap: What dividend safety score for Trevi Therapeutics Inc stockStock Surge & AI Optimized Trading Strategy Guides - moha.gov.vn
Published on: 2025-12-31 06:38:59 - moha.gov.vn
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - MSN
Trevi Therapeutics (TRVI) targets next phase of growth with leadership change - MSN
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change - Finviz
Flputnam Investment Management Co. Raises Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Is Trevi Therapeutics Inc. stock cheap at current valuationJuly 2025 PreEarnings & High Yield Equity Trading Tips - Улправда
Stifel Maintains Trevi Therapeutics (TRVI) Buy Recommendation - Nasdaq
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - MSN
Trevi Therapeutics stock price target raised to $18 by Stifel on cough drug potential - Investing.com Canada
First Week of TRVI February 2026 Options Trading - Nasdaq
TRVI: Stifel Raises Price Target and Maintains Buy Rating | TRVI Stock News - GuruFocus
What dividend safety score for Trevi Therapeutics Inc. stockJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - DonanımHaber
Why Trevi Therapeutics Inc. stock remains on buy listsJuly 2025 Chart Watch & Comprehensive Market Scan Reports - DonanımHaber
Can Trevi Therapeutics Inc. stock sustain market leadershipWeekly Profit Recap & Free Community Supported Trade Ideas - Улправда
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Trevi Therapeutics Earnings Notes - Trefis
Trevi Therapeutics stock hits all-time high of 14.01 USD By Investing.com - Investing.com Nigeria
Marshall Wace LLP Has $13.55 Million Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Stock Surges to Record High on Clinical and Strategic Momentum - AD HOC NEWS
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighTime to Buy? - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% HigherTime to Buy? - MarketBeat
Trevi Therapeutics stock hits all-time high of 14.01 USD - Investing.com
Trevi Therapeutics, Inc. $TRVI Shares Acquired by Vivo Capital LLC - MarketBeat
226,381 Shares in Trevi Therapeutics, Inc. $TRVI Bought by Prudential Financial Inc. - MarketBeat
Trevi Therapeutics appoints new CFO - MSN
Trevi Therapeutics Appoints New Chief Financial Officer - The Globe and Mail
Affinity Asset Advisors LLC Raises Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics appoints David Hastings as chief financial officer By Investing.com - Investing.com Nigeria
Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026 - marketscreener.com
Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026 - marketscreener.com
New Haven biotech names new CFO - Hartford Business Journal
Trevi Therapeutics appoints David Hastings as chief financial officer - Investing.com
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Geode Capital Management LLC - MarketBeat
Trevi Therapeutics appoints David Hastings as new CFO By Investing.com - Investing.com Nigeria
Trevi Therapeutics Taps David Hastings as CFO - Contract Pharma
Trevi Therapeutics appoints David Hastings as new CFO - Investing.com India
Trevi Therapeutics Appoints David Hastings as Chief Financial Officer - citybiz
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Panagora Asset Management Inc. - MarketBeat
Trevi Therapeutics Names David Hastings CFO - marketscreener.com
Trevi Therapeutics announces appointment of David Hastings as chief financial officer - marketscreener.com
Trevi Therapeutics Announces Appointment Of David Hastings As Chief Financial Officer - TradingView — Track All Markets
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - cnhinews.com
Trevi Therapeutics edges higher amid takeover speculation - MSN
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond - Seeking Alpha
Trevi Therapeutics stock hits all-time high at 13.92 USD By Investing.com - Investing.com Canada
2.52%
0.07%
자본화:
|
볼륨(24시간):